文献速递脊柱关节炎

中轴型脊柱关节炎关节外表现预测因素及其对TNF抑制剂处方模式的影响

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
PubMed 文献 · RMD Open · 2020-01-01

基于英国风湿病学会生物制剂注册中轴型脊柱关节炎队列2420例患者,分析关节外表现(AAU、IBD、银屑病)的预测因素及其对首选TNF抑制剂的影响。结果显示HLA-B27与AAU正相关、与银屑病和IBD负相关;既往AAU或IBD与更倾向选用阿达木单抗、较少选用依那西普相关。

要点

  • HLA-B27阳性与AAU发生正相关,与银屑病和IBD发生负相关。
  • 既往AAU或IBD患者更倾向首选阿达木单抗而非其他TNF抑制剂。
  • 既往AAU或IBD患者较少首选依那西普而非其他TNF抑制剂。

核心结论

  • HLA-B27阳性axSpA患者AAU发生率更高而银屑病和IBD发生率更低,符合当前病理生理认识。
  • 既往有AAU或IBD的患者更可能被处方阿达木单抗、较少接受依那西普,与单克隆TNF抑制剂在这些适应症上的更优疗效一致。

研究设计与样本

  • 来自英国风湿病学会生物制剂注册中轴型脊柱关节炎队列,纳入83个中心的2420例axSpA患者。
  • 收集临床与患者报告结局,比较有无关节外表现(AAU、IBD、银屑病)患者的生活方式因素。
  • 分析治疗前关节外表现与首选TNF抑制剂(阿达木单抗、依那西普、赛妥珠单抗)选择之间的关联。

主要发现

  • AAU与HLA-B27直接相关(IRR 1.95,95%CI 1.40至2.73),与曾经吸烟呈负相关(IRR=0.71,95%CI 0.55至0.92)。
  • 银屑病与HLA-B27呈负相关(IRR 0.54,95%CI 0.36至0.79),IBD与HLA-B27亦呈负相关(IRR 0.63,95%CI 0.43至0.91)。
  • 诊断AAU(OR 3.79,95%CI 2.11至6.80)或IBD(OR 5.50,95%CI 2.09至14.46)与偏好阿达木单抗而非其他TNF抑制剂相关。
  • 诊断AAU(OR 0.14,95%CI 0.06至0.33)或IBD(OR 0.17,95%CI 0.05至0.57)与较少偏好依那西普而非其他TNF抑制剂相关。

临床怎么用

  • 对于有AAU或IBD病史的axSpA患者,选择首选TNF抑制剂时可考虑优先选用阿达木单抗等单克隆抗体。
  • 对于有AAU或IBD病史的axSpA患者,选择TNF抑制剂时应较少选用依那西普。

局限性

  • 未来需确定关节外表现是否影响TNF抑制剂生存或有效性,以及不同药物间是否存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Extra-articular manifestations (EAMs) are important systemic features of axial spondyloarthritis (axSpA), which may influence the choice of tumour necrosis factor-inhibitor (TNFi). We examined the cumulative incidence and predictors of EAMs and the influence of these on first TNFi choice in a 'real-world' cohort of patients with axSpA. METHODS: Clinical and patient-reported outcomes of 2420 patients with axSpA from 83 centres were collected by the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. Lifestyle factors for EAMs (acute anterior uveitis (AAU), inflammatory bowel diseases (IBD), psoriasis) were compared with those without EAMs. Also, the association between pretreatment EAMs and choice of first TNFi (adalimumab, etanercept, certolizumab) was analysed. RESULTS: AAU was directly associated with human leukocyte antigen (HLA)-B27 (incidence rate ratio (IRR) 1.95, 95% CI 1.40 to 2.73) and inversely associated with ever-smoking (IRR=0.71, 95% CI 0.55 to 0.92). For both psoriasis and IBD, there was an inverse relationship with HLA-B27 (IRR 0.54, 95% CI 0.36 to 0.79 and IRR 0.63, 95% CI 0.43 to 0.91, respectively). A diagnosis of either AAU (OR 3.79, 95% CI 2.11 to 6.80) or IBD (OR 5.50, 95% CI 2.09 to 14.46) was associated with preference for adalimumab versus others. In contrast, a diagnosis of either AAU (OR 0.14, 95% CI 0.06 to 0.33) or IBD (OR 0.17, 95% CI 0.05 to 0.57) was associated with less preference for etanercept over other TNFi. CONCLUSION: The higher occurrence of AAU and lower occurrence of psoriasis and IBD in HLA-B27-positive patients with axSpA are consistent with current pathophysiology. Patients with previous AAU and IBD are more likely to be prescribed adalimumab and less likely to receive etanercept, consistent with the superior efficacy of monoclonal TNFi for these indications. Future work will determine whether EAMs influence TNFi survival, or effectiveness, and whether this varies between agents.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Derakhshan MH, Dean L, Jones GT, et al. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. RMD Open. 2020. PMID: 32641447. doi:10.1136/rmdopen-2020-001206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。